Small-cap investors had a busy session digesting a cluster of corporate actions, from portfolio companies edging toward stock market listings to a struggling consumer health group launching a formal sale process. Diamonds, cinema tickets and tungsten all featured, while a wave of fundraisings and contract wins rounded out a news-dense day across the boards.
Jangada's investee stakes edge toward IPO paydays
Jangada Mines (LSE:JAN), the Brazil-focused natural resources investor, saw its shares rise 13.7% to 0.7675p after revealing that two of its portfolio holdings are moving closer to public listings. Investee Fodere Titanium, in which Jangada holds a 7.8% stake following a roughly £1 million investment in 2021, has made significant progress toward a US listing, while fellow investee Axies Ventures, 4.4% owned after £150,000 invested across two tranches in 2022 and 2026, has separately signalled its own IPO ambitions.
Fodere, now rebranded Fodere Critical Minerals, has pivoted its near-term focus to a proposed pre-commercial plant in Mississippi, backed by a memorandum of understanding for feedstock from Tronox's Hamilton site. A US investment bank is leading a proposed $10 million to $15 million pre-IPO financing round targeted for completion by the end of October, ahead of a possible US listing in the first half of 2027. Axies, which holds copper and copper-gold projects in Cyprus and Canada, believes its portfolio will be ready for an IPO in the fourth quarter at what Jangada describes as a significant multiple to its entry price.
"We have significant capital invested in two companies that are both progressing towards potential liquidity events," said Brian McMaster, Chairman, Jangada.
The dual IPO tracks give Jangada a rare visible path to crystallising value on investments that have sat quietly on its balance sheet for years, without diluting existing shareholders to fund its Brazilian work programmes. With more than £1 million in cash already in hand, the company is positioned to treat any Fodere or Axies liquidity event as pure upside rather than a lifeline, a materially different setup from the dilutive financings that typically accompany small-cap resource stories.
Gem Diamonds swings to profit as revenue jumps
Gem Diamonds (LSE:GEMD), operator of the Letšeng mine in Lesotho, surged 70.4% to 10.65p after reporting revenue of $59.7 million for the six months to 30 June, up 32% on the $45.4 million recorded a year earlier. The swing to profitability came despite carats sold falling 4%, as an average price of $1,395 per carat, against $1,008 previously, more than compensated for the lower volumes.
Underlying EBITDA reached $8.6 million, reversing a negative $2.6 million a year earlier, aided by cost containment measures introduced in July 2025 and extended royalty relief at Letšeng. "The structural cost measures implemented in July 2025, as well as the extension of Letšeng's royalty relief, are delivering tangible results," said chief executive Clifford Elphick, adding that the initiatives have materially reduced the cost base as the company navigates a challenging global diamond market. Cash climbed to $20.2 million from $3.8 million at the end of December, with net debt trimmed to just $0.5 million.
The scale of the share price reaction reflects how thin the market's expectations had become for a miner that spent much of the past two years absorbing weak diamond prices. A return to underlying profitability, paired with a sharply repaired balance sheet, gives Gem Diamonds room to argue its cost-cutting programme has structurally changed the business rather than merely cushioned a downturn.
Futura Medical raises £1.6 million, launches formal sale process
Futura Medical (LSE:FUM) has conditionally raised approximately £1.6 million through a placing and subscription while simultaneously launching a formal sale process under the Takeover Code, opening the door to a sale of the company or its assets. Shares in the developer of erectile dysfunction treatment Eroxon and female sexual health platform WSD4000 fell 15.15% to 0.28p as 801 million new shares were issued at 0.2p, a discount of approximately 37.6% to the prior close of 0.32p.
A further retail offer via the BookBuild platform aims to raise up to £150,000, with the enlarged fundraising set to leave new shares representing approximately 60.1% of the enlarged share capital. The board argued its current market valuation fails to reflect the strategic value of its pipeline, pointing to WSD4000's estimated peak annual consumer sales potential of over $400 million, against a combined figure of more than $250 million for Eroxon and Eroxon Intense.
The decision to pair a deeply discounted raise with a formal sale process signals a board that has concluded it cannot close the valuation gap alone. Proceeds extend the cash runway into February 2027 and fund the sale process itself, but the heavy dilution and steep discount suggest existing shareholders are being asked to bridge the company to a trade outcome rather than a standalone recovery.
Futura Medical launches £150,000 retail offer alongside £1.6 million fundraise
Futura Medical has opened a retail offer to existing shareholders via the BookBuild platform, seeking up to £150,000 through the issue of up to 75 million new shares at 0.2p each. The offer runs alongside the separately announced £1.6 million conditional fundraising comprising a firm placing, a conditional placing and a conditional subscription, with shares trading at 0.28p, down 15.15% on the day.
The 0.2p issue price represents a discount of approximately 37.63% to the closing middle market price of 0.32p on 2 September. Futura said it valued the support of its retail shareholder base, which has backed the company alongside institutional investors since its AIM admission in 2003. Turner Pope Investments is acting as retail offer coordinator, with a minimum subscription of £100 per investor and no upper limit; the offer opened at 7:05am on 3 September and closes at 4:30pm the following day.
Extending participation to retail holders on the same discounted terms as institutions is a modest gesture of goodwill from a board that otherwise has little room to manoeuvre, given the scale of dilution already under way and the uncertain outcome of the parallel sale process.
Everyman cinema bookings surge, EBITDA jumps
Everyman Media Group (LSE:EMAN) swung to a statutory pre-tax profit of £1.9 million in the first half, with shares dipping 1.79% to 55.0p despite the improvement. The premium cinema operator outpaced UK box office growth over the period, a performance the company credited to strong programming and its differentiated venue format.
The group is eyeing new venue openings in 2027 as it looks to extend its estate, betting that premium, food-and-drink-led cinema experiences continue to outperform the wider exhibition market even as streaming competition persists.
Tribal grows H1 recurring revenue as FY26 guidance reiterated
Tribal Group (LSE:TRB) lifted first-half revenue by 7.1% and annual recurring revenue by 9.7%, moving to a net cash position even as shares slipped 3.17% to 61.0p. The edutech firm, which supplies software to universities and colleges, said the improved cash position reflects stronger underlying trading momentum through the period.
Management guided FY26 comfortably in line with market expectations, giving investors reassurance that the recurring revenue growth is translating into durable cash generation rather than one-off gains.
Brooks Macdonald guides ahead of expectations
Brooks Macdonald Group (LSE:BRK) shares rose 1.99% to 1499.25p after the wealth manager swung back to positive annual net flows in its full year to 30 June, reversing prior outflow pressure. The company said FY27 performance is tracking marginally ahead of current market expectations.
The return to positive flows marks an inflection point for a wealth manager that has spent recent years defending its client base against fee competition, with the ahead-of-expectations guidance suggesting the turnaround has legs into the new financial year.
Zinc Media wins Middle East feature film deal
Zinc Media Group (LSE:ZIN) has been commissioned to produce a $6.1 million feature film for an unnamed Middle East institution, sending shares up 6.19% to 60.0p. The AIM-quoted production company said the commission ranks among the largest single productions it has undertaken in the region.
Landing a contract of this scale from an institutional Middle East client adds a substantial, higher-margin project to Zinc's pipeline and underscores the group's push to diversify beyond its traditional UK broadcast commissioning base.
East Star finds new chargeability anomaly at Snowy gold target
East Star Resources (LSE:EST) has identified an east-west striking IP anomaly at its Snowy epithermal target in Kazakhstan, with shares climbing 5.97% to 7.1p on the update. The survey, however, fell short of its designed charge input, leaving the full extent of the anomaly still to be resolved.
The partial result keeps Snowy on the exploration radar without yet delivering a conclusive read, meaning further survey work will likely be needed before the target can be properly ranked against East Star's other Kazakh prospects.
Journeo lands Elizabeth line orders
Journeo (LSE:JNEO) shares rose 3.86% to 538.0p after subsidiary Infotec secured initial purchase orders from GTS Rail Operations, the first tranche of a wider £2.55 million programme on London's Elizabeth line.
The order gives Journeo visibility over a multi-tranche revenue stream tied to one of the capital's flagship rail routes, reinforcing its position as a supplier of passenger information systems to major UK transport operators.
IQE lands new Quintessent order as laser tech nears customers
Iqe (LSE:IQE) will supply Quantum Dot Laser epiwafers to Quintessent under an extended agreement, with shares up 3.18% to 45.4p. The deal supports customer sampling ahead of a planned commercial launch of the underlying laser technology.
The extension keeps IQE embedded in the development pipeline of an emerging photonics customer, positioning the compound semiconductor group to benefit if Quintessent's laser technology progresses from sampling to volume commercial orders.
Renalytix launches £1 million retail offer
Renalytix (LSE:RENX), trading at 4.15p, has opened a Winterflood retail offer for up to £1 million, running alongside a separately announced £10.1 million placing and subscription, both priced at 6p a share.
Pricing the retail offer above the current market price signals confidence from participating institutions in the placing, though it also means retail investors are being asked to back the diagnostics company at a premium to where the stock currently trades.
Kazera settles Fujax debt, weighs £500k raise
Kazera Global (LSE:KZG) has agreed a $1 million settlement with Fujax over a legacy prepayment dispute, with shares jumping 23.81% to 1.95p. The company is now exploring an equity raise of up to £500,000, a step that triggered a temporary suspension of its shares under AIM's new Capital Access Window process.
Resolving the Fujax dispute removes a legacy overhang that had clouded the company's balance sheet, though the need for fresh equity so soon after settlement suggests the cash cost of the settlement was not trivial for a company of Kazera's size.
Sealand launches AI content platform MercuryGlitter
Sealand Capital Galaxy (LSE:SCGL) has launched MercuryGlitter, an AI-generated content platform targeting advertising, brand marketing and enterprise communications, with shares dipping 1.26% to 0.4325p.
The launch pushes Sealand further into the crowded generative AI content space, a market where differentiation and enterprise sales traction will determine whether the platform becomes a meaningful revenue line rather than a speculative side project.
Blackbird says paid subscriber numbers jump 75% in six weeks
Blackbird (LSE:BIRD) shares climbed 14.95% to 1.2644p after the company reported a 75% jump in paid subscriber numbers over six weeks, driven by improved free-to-paid conversion and a renewed marketing push.
The board flagged the need to sustain the momentum, a caveat that tempers the headline growth figure and points to marketing spend, rather than organic pull, as a key driver so far.
Solvonis wins European patent allowance for PTSD candidate SVN-114
Solvonis Therapeutics (LSE:SVNS) rose 10.64% to 0.13p after the European Patent Office granted composition-of-matter allowance strengthening protection roughly the company's lead PTSD drug candidate, SVN-114.
Composition-of-matter protection is the strongest form of patent cover available to a drug developer, giving Solvonis a firmer intellectual property moat as it advances SVN-114 through further development.
Gulf Marine Services secures one-year vessel extension
Gulf Marine Services (LSE:GMS) shares edged up 0.77% to 18.34p after a National Oil Company customer exercised a one-year option on a GMS Small-class vessel operating in the GCC, with terms unchanged.
The extension provides continued revenue visibility from an established customer relationship, reinforcing utilisation across the company's fleet in a region that remains core to its charter book.
Sunda Energy prospect estimate pitched at 3Tcf net
Sunda Energy (LSE:SNDA) shares rose 5.08% to 3.1p after operator Tetragon Energy's updated study more than doubled net gas Prospective Resources at the Halcon prospect in the Philippines, in which Sunda holds a 37.5% working interest.
The upgraded resource estimate materially raises the scale of the potential prize at Halcon, adding weight to the case for further appraisal work on the licence.
Talon starts maiden drilling at Eagle Lake gold project
Talon Resources (LSE:TAR) has begun a fully funded 11-hole diamond drilling campaign at its Eagle Lake project in Ontario, with shares up 5.38% to 1.37p. Drilling started at the highest-priority East Fornieri Bay target.
Being fully funded into a maiden drill programme removes near-term financing risk for Talon, letting the market focus purely on the geological results as they come through.
Tungsten West posts £7.9 million operating loss as Hemerdon restart advances
Tungsten West (LSE:TUN) narrowed its operating loss to £7.9 million and ended the year with cash reserves up sharply, after raising £43 million to fund construction at its Hemerdon mine. Shares rose 1.79% to 49.369p.
The strengthened cash position gives Tungsten West runway to push through the restart phase at Hemerdon, though the continuing operating loss underscores that the project has yet to generate the revenue needed to offset development costs.
Bezant nears first concentrate at Hope & Gorob copper-gold mine
Bezant Resources (LSE:BZT) expects first ore through its Tsoaxaub processing plant this month, with shares up 2.27% to 0.1534p. A Phase II review has lifted the project's estimated life of mine to roughly 35 years.
The extended mine life materially improves the long-run economics of Hope & Gorob, transforming what had been a shorter-life project into one with a multi-decade production horizon just as first ore approaches.
Synectics wins bus surveillance contract
Synectics (LSE:SNX) shares were roughly flat at 190.2p after subsidiary Ocular Integration secured a contract to fit on-vehicle surveillance technology across 220 new buses for a UK regional authority, in a deal worth £1.4 million.
The contract adds another public transport security win to Synectics' order book, an area where recurring maintenance and service revenue typically follows the initial installation.
Strategic Minerals agrees final terms to sell Leigh Creek copper mine
Strategic Minerals (LSE:SML) has locked in definitive terms to sell its Leigh Creek Copper Mine to Cuprum Metals for a layered package of cash, shares, royalties and earn-outs, with shares slipping 0.51% to 5.472p. Proceeds are earmarked for the Redmoor tungsten-tin-copper project in Cornwall.
Redirecting Leigh Creek proceeds into Redmoor signals a strategic pivot toward a UK critical minerals project, trading a producing but presumably lower-growth Australian asset for exposure to a domestic development story with royalty and earn-out upside retained.
Rockfire drilling resumes at Molaoi zinc project
Rockfire Resources (LSE:ROCK) shares rose 5.71% to 0.111p as diamond drilling resumed at the Molaoi zinc deposit in Greece, with early metallurgical results pointing to lower processing costs.
Lower projected processing costs would improve Molaoi's economics directly, giving Rockfire a tangible reason to keep advancing the project toward a development decision.
